Author: Tempest Therapeutics

Posted Date:

June 4, 2026

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

Tempest Therapeutics

June 4, 2026
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Tempest Therapeutics

May 29, 2026
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Tempest Therapeutics

May 27, 2026
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest Therapeutics

May 26, 2026
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Therapeutics

May 25, 2026
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Therapeutics

May 24, 2026
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Tempest Therapeutics

May 23, 2026
Tempest Therapeutics Announces Up To $6 Million Private Placement

Tempest Therapeutics

May 21, 2026
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Tempest Therapeutics

April 30, 2026
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Tempest Therapeutics

February 25, 2026